Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

Mon, 14th Nov 2022 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 13% at 184.96 pence, 12-month range 1.30p - 194.00p. The Hong Kong-based biopharmaceutical company reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. The drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase three study in 703 patients, which the firm explains is clinically meaningful. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

----------

Midatech Pharma PLC, up 7.2% at 6.49 pence, 12-month range 6.00p - 24.63p. Enrols the first patient into its phase one study of MTX-110 in recurrent glioblastoma, a type of cancer that appears in the brain or spinal cord. The study is an open-label, dose escalation study to assess the feasibility and safety of intermittent infusions of MTX-100. Cardiff-based biotechnology firm Midatech says it previously reported "encouraging results" from a phase one study of MTX-110 in diffuse intrinsic pontine glioma, a type of tumour that is located on the brain stem.

----------

SRT Marine Systems PLC, up 7.6% at 48.95 pence, 12-month range 23.60p - 55.00p. The maritime surveillance, analytics and management systems developer reports a steep increase in interim revenue as it swings to a pretax profit of GBP2.1 million from a loss of GBP3.1 million. In the six months to September 30, SRT Marine Systems reports revenue of GBP18.8 million, multiplied from GBP4.7 million the previous year. This, it adds, is despite ongoing component supply issues. Chief Executive Simon Tuckers expects this strong performance to continue going forward as long-term demand stays robust.

----------

AIM - LOSERS

----------

Tremor International Ltd, down 26% at 281.00 pence, 12-month range 2.90p - 330.60p. Swings to a total comprehensive IFRS loss of USD5.2 million in the three months ended September 30, from a profit of USD10.2 million the previous year. Revenue in the quarter drops 19% year-on-year to USD70.9 million from USD87.0 million. Despite the drop in profit and revenue, Tremor says it remains "well-positioned" to benefit from "anticipated industry secular growth trends" which it expects to help mitigate potential negative effects. Full-year adjusted earnings before interest, taxation, depreciation, and amortization is expected at USD140 million.

----------

Shanta Gold Ltd, down 12% at 9.60 pence, 12-month range 6.50p - 14.00p. Three companies which previously expressed interest in the East Africa-focused gold producer, developer and explorer say they do not intend to make an offer for the firm. In October, Shanta received approaches from Shandong Gold Group Co Ltd, Yintai Gold Co Ltd and Chaarat Gold Holdings Ltd. These companies have since decided not to proceed with an offer. Nonetheless, Shanta says it continues to believe in the strength of its business and the potential of its portfolio.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more
26 May 2023 08:56

Hutchmed China celebrates FDA review, teases new data at ASCO meeting

(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.

Read more
5 May 2023 15:57

UK shareholder meetings calendar - next 7 days

Monday 8 May 
no events scheduled 
Tuesday 9 May 
Caledonia Mining Corp PLCAGM
Direct Line Insurance Group PLCAGM
Foxtons Group PLCAGM
Hostelworld Group PLCAGM
IWG PLCAGM
Just Group PLCAGM
Midwich Group PLCAGM
Osirium Technologies PLCAGM
Windward LtdAGM
Wednesday 10 May 
abrdn PLCAGM
Antofagasta PLCAGM
Cenkos Securities PLCAGM
Ecora Resources PLCAGM
H&T Group PLCAGM
Harbour Energy PLCAGM
Jupiter Fund Management PLCAGM
Literacy Capital PLCAGM
Luceco PLCAGM
Marshalls PLCAGM
National Express Group PLCAGM
Renewables Infrastructure Group LtdAGM
Rentokil Initial PLCAGM
Seplat Energy PLCAGM
Spirax-Sarco Engineering PLCAGM
TClarke PLCAGM
Thursday 11 May 
88 Energy LtdAGM
Cairn Homes PLCAGM
Capita PLCAGM
Clarkson PLCAGM
Costain Group PLCAGM
Eleco PLCAGM
Eurocell PLCAGM
FBD Holdings PLCAGM
Genedrive PLCGM re Equity Prepayment Facility
Genel Energy PLCAGM
Gresham House PLCAGM
Gym Group PLCAGM
Hiscox LtdAGM
Irish Continental Group PLCAGM
John Wood Group PLCAGM
MyHealthChecked PLCAGM
OSB Group PLCAGM
Poolbeg Pharma PLCAGM
Rolls-Royce Holdings PLCAGM
Serinus Energy PLCAGM
Uniphar PLCAGM
Videndum PLCAGM
WAG Payment Solutions PLCAGM
Friday 12 May 
Balfour Beatty PLCAGM
Derwent London PLCAGM
Goodbody Health LtdAGM
GreenRoc Mining PLCAGM
Hutchmed (China) LtdAGM
Itim Group PLCAGM
Itsarm PLCGM re delisting from AIM
Wheaton Precious Metals CorpAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
18 Apr 2023 12:30

Hutchmed's gastric cancer treatment accepted for review in China

(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.

Read more
18 Apr 2023 09:55

Hutchmed gets Chinese approval for fruquintinib new drug application

(Alliance News) - Hutchmed (China) Ltd on Tuesday said the China National Medical Products Administration accepted its new drug application for fruquintinib in combination with paclitaxel.

Read more
4 Apr 2023 13:56

Hutchmed to start registration phase enrolments for two treatments

(Alliance News) - Hutchmed China Ltd on Tuesday said it will start registration phase enrolments for two of its prospective treatments under study, HMPL-453 and savolitinib.

Read more
31 Mar 2023 13:47

Hutchmed completes rolling FDA submission for colorectal cancer drug

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced the completion of its rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for its oral inhibitor 'fruquintinib'.

Read more
31 Mar 2023 12:15

Hutchmed submits new drug application to US FDA for cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Friday said it has completed the rolling submission of a new drug application for its fruquintinib cancer drug to the US Food & Drug Administration.

Read more
14 Mar 2023 14:23

Hutchmed China inks global licensing deal with Takeda on fruquintinib

(Alliance News) - Hutchmed China Ltd on Tuesday said it closed a license agreement with a subsidiary of Tokyo-based drug maker Takeda Pharmaceutical Co Ltd for fruquintinib.

Read more
8 Mar 2023 14:07

DIRECTOR DEALINGS: Hutchmed CFO banks GBP4 million; Haleon chair buys

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
28 Feb 2023 11:43

Hutchmed expects revenue climb from oncology, immunology division

(Alliance News) - Hutchmed (China) Ltd expects a sharp rise in revenue from its oncology and immunology-focused arm, as the biopharmaceutical firm looks forward to a productive 2023.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.